Recent developments in steroid-responsive pancreatitides (autoimmune pancreatitis)

Area of Science:

• Gastroenterology
• Immunology
• Pancreatology

Background:

• Two distinct steroid-responsive chronic fibro-inflammatory pancreatic diseases exist: autoimmune pancreatitis (AIP) types 1 and 2.
• Recent literature suggests using 'AIP' for type 1 and 'idiopathic duct-centric chronic pancreatitis' (IDCP) for type 2.

Purpose of the Study:

• To review recent progress in understanding and managing type 1 AIP and type 2 IDCP.
• To highlight advancements in diagnostic criteria and therapeutic strategies.

Main Methods:

• Review of recent clinical findings and treatment outcomes for AIP and IDCP.
• Application of International Consensus Diagnostic Criteria for AIP.
• Evaluation of therapeutic strategies including corticosteroids, rituximab, and maintenance therapy.

Main Results:

• Clinical features and long-term outcomes for both AIP and IDCP are well-characterized with excellent prognoses.
• Diagnostic strategies have improved with the International Consensus Diagnostic Criteria for AIP.
• Corticosteroids are primary treatment; rituximab is effective for AIP remission induction/maintenance; IDCP requires steroids without maintenance therapy.
• Conflicting results exist regarding malignancy risk in AIP.

Conclusions:

• Treatment and follow-up guidelines for AIP and IDCP are evolving.
• Rituximab is a viable option for AIP remission, while IDCP responds well to steroids alone.
• Both AIP and IDCP demonstrate excellent long-term prognoses.